학술논문
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
Document Type
Article
Author
Ma, Jimmy; Nance, Robin M; Delaney, Joseph A C; Whitney, Bridget M; Bamford, Laura; Gravett, Ronnie M; Moore, Richard D; Napravnik, Sonia; Mayer, Kenneth H; Jacobson, Jeffrey M; Christopoulos, Katerina; Burkholder, Greer A; Keruly, Jeanne; Eron, Joseph J; Martin, Jeffrey; Cachay, Edward R; Saag, Michael S; Crane, Heidi M; Kitahata, Mari M
Source
Subject
*HIV infection risk factors
*HIV infections
*HIV integrase inhibitors
*TENOFOVIR
*CROSS-sectional method
*ANTIRETROVIRAL agents
*HEALTH outcome assessment
*REGRESSION analysis
*DESCRIPTIVE statistics
*DATA analysis software
*LONGITUDINAL method
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
Among 14 049 people with human immunodeficiency virus in care in 2019–2020, 96% were treated with antiretroviral therapy (ART). Current antiretroviral treatment patterns highlight high uptake of guideline-recommended ART regimens including second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naive individuals initiating ART. [ABSTRACT FROM AUTHOR]